Triglav Skladi D.O.O. Invests $727,000 in Zoetis Inc. (NYSE:ZTS)

Triglav Skladi D.O.O. bought a new stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 4,460 shares of the company's stock, valued at approximately $727,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC boosted its stake in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after buying an additional 140 shares during the period. Rakuten Securities Inc. raised its position in shares of Zoetis by 5,533.3% during the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock worth $28,000 after acquiring an additional 166 shares in the last quarter. Navigoe LLC acquired a new stake in shares of Zoetis during the 4th quarter worth about $30,000. Murphy & Mullick Capital Management Corp acquired a new stake in shares of Zoetis during the 4th quarter worth about $44,000. Finally, Asset Planning Inc acquired a new stake in shares of Zoetis during the 4th quarter worth about $58,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on ZTS. UBS Group cut their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Barclays lifted their price target on Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research report on Friday, February 14th. Morgan Stanley cut their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. Wall Street Zen raised Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Finally, Stifel Nicolaus cut their price target on Zoetis from $180.00 to $165.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $212.75.

Zoetis Price Performance

ZTS stock traded up $0.66 on Thursday, reaching $162.10. 2,873,540 shares of the company's stock were exchanged, compared to its average volume of 2,522,978. The stock has a fifty day moving average of $156.58 and a 200-day moving average of $165.05. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $200.33. The firm has a market cap of $72.17 billion, a PE ratio of 29.63, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.22 billion for the quarter, compared to analyst estimates of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Zoetis's revenue was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.38 earnings per share. As a group, equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.23%. The ex-dividend date is Friday, July 18th. Zoetis's payout ratio is currently 35.91%.

Insider Activity at Zoetis

In related news, Director Willie M. Reed sold 1,210 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares in the company, valued at $2,682,770. This trade represents a 2.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.18% of the company's stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.